CPhI Madrid 2009
The Infa Group is proud to acknowledge the outstanding reception we received at CPhI Madrid in October. We wish to thank all those who visited our booth: customers, suppliers, and friends. This was another successful industry meeting for the Group, which includes our four manufacturing units: Labochim, Sifavitor, Derivados Quimicos, and Kylolab and sales and marketing offices in Italy, Germany, Switzerland, and the US.
Our portfolio of pharmaceutical APIs continues to expand as our Research and Development efforts bring new molecules to our product offering. The Infa product portfolio now includes more than 100 APIs sold worldwide.
CPhI provides an excellent venue for meeting with our valued suppliers and customers from around the world as well as making new contacts for potential future business. We look forward to meeting with you at CPhI 2010 in Paris.

API producer Labochim
API producer Labochim is proud to announce that its manufacturing plant in Segrate, Italy has been issued an Establishment Inspection Report (EIR) from US FDA classifying the facility as acceptable for API manufacturing based upon an inspection conducted from May 25th through May 29th, 2009. The inspection covered two pre-approvals for New Drug Applications (NDAs) and one approval for Abbreviated New Drug Applications (ANDA).
Labochim is routinely inspected by various regulatory agencies, including AIFA (the Italian Ministry of Health). The most-recent FDA inspection was November 19-22, 2007.
This has been a busy year for the Infa Group. Sister company Sifavitor also was inspected by US FDA in March, 2009. The inspection covered seven pre-approvals for ANDAs. The Sifavitor facility in Lodi, Italy was also found acceptable.
Regulatory compliance is a strategic focus at Labochim and all facilities within the Infa Group. Our history of successful inspections since the 1970’s has contributed to the Group’s growth worldwide.

Milan, September 2009

It is with great pleasure we announce the outcome of Sifavitor’s recent US FDA inspection.
The Sifavitor manufacturing facility in Lodi has been classified by the US FDA as acceptable for API manufacturing. This is indicative of the ongoing commitment of Sifavitor and the entire Infa Group to excellence in the manufacturing of quality active pharmaceutical ingredients.